From PGF(2alpha)-isopropyl ester to latanoprost: a review of the development of xalatan: the Proctor Lecture.
Stjernschantz
J W
JW
Department of Neuroscience, Unit of Pharmacology, Box 593, Uppsala University, S-751 24 Uppsala, Sweden. johan.stjernschantz@neuro.uu.se
D000818:Animals; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D001363:Awards and Prizes; D015237:Dinoprost / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D005901:Glaucoma / Q000188:drug therapy; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D008548:Melanosis / Q000139:chemically induced; D015394:Molecular Structure; D009885:Ophthalmology; D011461:Prostaglandins F, Synthetic / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D012137:Respiratory System / Q000187:drug effects; D012958:Societies, Scientific
D000959:Antihypertensive Agents; D011461:Prostaglandins F, Synthetic; C041158:prostaglandin F2 isopropyl ester; D000077338:Latanoprost; D015237:Dinoprost